Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis

Chiu, Hedva; Hollingworth, Samantha; Driel, Mieke van; Magin, Parker; Benham, Helen

doi:10.1093/rheumatology/kew460

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited access to health resources and suboptimal health behaviors are additional reasons for treatment inequality observed in low SES patients [ 13 , 14 ]. Despite the crucial role of SES in the RA treatment course, biologics use and its association with SES have been underreported [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency

Kim,

Lee,

et al. 2024

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims: This cross-sectional study aimed to investigate biologics treatment disparities in rheumatoid arthritis (RA) patients based on socioeconomic status (SES). Methods: Data from the KOrean Observational Study Network for Arthritis (KORONA) database were analyzed to assess various factors associated with SES, health behaviors, and biologics use. Logistic regression and structured equation modeling (SEM) were utilized for data analysis. Results: Among 5,077 RA patients included, 393 (7.7%) patients were identified as biologics users. Within the entire cowww.kjim.org

show abstract

Section: Introductionmentioning

confidence: 99%